Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China
DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company...